GlassScriptPhysician profile
Miranda S Mckellar
NPI 1134654551
$583.85
in general payments reported to CMS, 2019-2025
12 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $51.43 · 2023: $118 · 2024: $196 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $142.43 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $104.40 | 2022-2024 | |
| Amgen INC. | $59.05 | 2023-2025 | Evenity, Prolia, Prolia |
| Novo Nordisk INC | $54.55 | 2024-2025 | Wegovy |
| Lilly USA, LLC | $45.89 | 2023-2024 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $36.82 | 2025 | Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.41 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $30.77 | 2023-2025 | |
| Dexcom, INC. | $24.15 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.22 | 2024 | Xifaxan |
| Insulet Corporation | $18.24 | 2025 | Omnipod |
| Idorsia Pharmaceuticals US INC | $13.92 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Mckellar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.